Clicky

Vor Biopharma Inc.(VOR)

Description: Vor Biopharma, Inc. develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It offers VOR33, an eHSC product candidate that is in preclinical development to treat acute myeloid leukemia (AML). The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML cancer cells. Vor Biopharma, Inc. was incorporated in 2015 and is based in Cambridge, Massachusetts.


Keywords: Cancer Acute Myeloid Leukemia Proteins Tyrosine Kinase Receptors Therapies For Cancer Haematopoiesis

Home Page: www.vorbio.com

VOR Technical Analysis

100 Cambridgepark Drive
Cambridge, MA 02140
United States
Phone: 617 655 6580


Officers

Name Title
Dr. Robert Ang M.B.A., M.D., MBBS Pres, CEO & Director
Dr. Tirtha Chakraborty Ph.D. Chief Scientific Officer
Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. Scientific Founder & Chairman of Scientific Advisory Board
Dr. Nathan D. Jorgensen M.B.A., Ph.D. Chief Financial Officer
Ms. Tania Philipp Chief People Officer
Dr. Robert G. Pietrusko Pharm.D., Pharm. D. Chief Regulatory & Quality Officer
Mr. John C. King M.B.A. Chief Commercial Officer
Dr. Veit Schmelmer Ph.D. Sr. VP of Program & Alliance Management
Dr. Eyal C. Attar M.D. Chief Medical Officer

Exchange: NASDAQ

Country: US

Currency: US Dollar ($)

Forward PE: 0
Trailing PE: 0
Price-to-Book MRQ: 1.5785
Price-to-Sales TTM: 0
IPO Date: 2021-02-05
Fiscal Year End: December
Full Time Employees: 135
Back to stocks